Non-alcoholic Steatohepatitis (NASH)

NASH is a serious condition in which fat accumulates in liver tissue in people who consume little or no alcohol. It is the most severe form of non-alcoholic fatty liver disease (“NAFLD”), which in some individuals can progress to fibrosis (scarring) and ultimately hepatocellular carcinoma (liver cancer).
According to a new report published by Allied Market Research, “Global Opportunity Analysis and Industry Forecast, 2021-2025," the global NASH market was valued at $1.17 Billion in 2017, and is expected to reach $21.4 Billion by 2025, growing at a CAGR of 58.4% from 2021 to 2025. Currently, there are no US FDA approved treatments for NAFLD or NASH.

Market Projection*

(in US$ Billions)

*According to a new report published by Allied Market Research, “Global Opportunity Analysis and Industry Forecast, 2021-2025"